Supplementary Methods from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

Mitra Ghosh, Taraswi; Mazumder, Suman; Davis, Joshua; Yadav, Jyoti; Akinpelu, Ayuba; Alnaim, Ahmed; Kumar, Harish; Waliagha, Razan; Church Bird, Allison E.; Rais-Bahrami, Soroush; Bird, R. Curtis; Mistriotis, Panagiotis; Mishra, Amarjit; Yates, Clayton C.; Mitra, Amit K.; Arnold, Robert D.

doi:10.1158/2767-9764.23709906.v1

Supplementary Methods from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

journal contribution

posted on 2023-07-19, 14:20 authored by Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, Jyoti Yadav, Ayuba Akinpelu, Ahmed Alnaim, Harish Kumar, Razan Waliagha, Allison E. Church Bird, Soroush Rais-Bahrami, R. Curtis Bird, Panagiotis Mistriotis, Amarjit Mishra, Clayton C. Yates, Amit K. Mitra, Robert D. Arnold

Supplementary Methods

Funding

N/A

History

ARTICLE ABSTRACT

The utilization of metronomic-like dosing regimens of topotecan alone and in combination with DTX resulted in the suppression of makers associated with EMT and stem-like cell populations in AVPC models. The identification of molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression were achieved using bulk RNA-seq and single-cell-omics methodologies.

Usage metrics

Keywords

Genitourinary Cancers Prostate cancer Single Cell Technologies Drug Resistance Translational Research Chemotherapy Combination chemotherapy Small Molecule Agents Topoisomerase agents Tubulin agents

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplementary Methods from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

Funding

N/A

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports